Quantitative MRI evaluation of bone marrow in sickle cell disease: relationship with haemolysis and clinical severity

• Published in: Clinical radiology Vol. 78; no. 3; pp. e268 - e278
• Main Authors: Lins, C. Freitas, Salmon, C.E. Garrido, Amorim de Souza, L., Quesado, R.C. Saldanha, de Souza Moraes, R., Silva-Pinto, A.C., Matos, M. Almeida, Nogueira-Barbosa, M.H.
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 01.03.2023
• Subjects: Anemia, Sickle Cell - complications; Anemia, Sickle Cell - diagnostic imaging; Biomarkers; Bone Marrow; Cross-Sectional Studies; Hemoglobin SC Disease; Hemoglobin, Sickle; Hemolysis; Humans
• ISSN: 0009-9260; 1365-229X
• DOI: 10.1016/j.crad.2022.11.014

To evaluate bone marrow fat fraction using the Dixon technique (FFDix) of magnetic resonance imaging (MRI) as a potential biomarker of haemolysis and clinical severity in the overall assessment and follow-up of sickle cell disease (SCD) patients. The present study was a cross-sectional study in which healthy individuals and SCD patients (matched for age, sex, and weight) were subjected to MRI of the lumbar spine and pelvis to quantify FFDix in the bone marrow using the Dixon technique. SCD severity was analysed by clinical and laboratory data, and an online calculator. A high degree of haemolysis was defined using the cut-off values haemoglobin (Hb) ≤10 g/dl, lactate dehydrogenase (LDH) ≥325 U/l, reticulocytes ≥3% and total bilirubin (TB) ≥1.2 mg/dl. Pearson's correlation, receiver operating characteristic (ROC) curve and binary logistic regression analysis were performed. Forty-eight SCD patients (26 homozygous: HbSS and 22 compound heterozygous: HbSC) and 48 healthy individuals participated in the study. FFDix was lower in SCD patients than in the control group, showing even lower values in the HbSS subtype and patients with a higher degree of haemolysis. HbSC patients with a higher degree of haemolysis using hydroxyurea (medium dosage 9.8 mg/kg/day) had lower FFDix. ROC curves and odds ratios for detecting patients with a higher degree of haemolysis at the different FFDix measurement sites demonstrated excellent performance: iliac bones (cut-off ≤16.75%, AUC = 0.824, p<0.001), femoral heads (cut-off ≤46.7%, AUC = 0.775, p=0.001), lumbar vertebrae (cut-off ≤7.8%, AUC = 0.755, p=0.002). Decreased FFDix is indicative of higher degree of haemolysis and SCD severity with great potential as a non-invasive biomarker contributing to the overall assessment and follow-up of SCD patients.